Clinical trial

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight

Name
18685
Description
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.
Trial arms
Trial start
2023-11-17
Estimated PCD
2025-06-27
Trial end
2025-09-05
Status
Recruiting
Phase
Early phase I
Treatment
LY3305677
Administered SC. ISA specific interventions will be listed in the ISA.
Arms:
LY3305677 Obesity ISA OXA1
LY3841136
Administered SC. ISA specific interventions will be listed in the ISA.
Arms:
LY3841136 Obesity ISA LAA1
Placebo
Administered SC. ISA specific interventions will be listed in the ISA.
Arms:
LY3305677 Obesity ISA OXA1, LY3841136 Obesity ISA LAA1
Size
390
Primary endpoint
Number of Participants Allocated to Each ISA
Baseline to Week 48
Eligibility criteria
Inclusion Criteria: * Have a Body Mass Index (BMI) ≥30 kilograms per square meter (kg/m²) * Have a BMI ≥27 kg/m²and \<30 kg/m² with at least one of the following weight-related comorbidities: * hypertension: on blood pressure (BP)-lowering medication. * dyslipidemia: on lipid-lowering medication * cardiovascular (CV) disease: for example, ischemic CV disease, New York Heart Association (NYHA) Functional Classification Class I or II heart failure. * obstructive sleep apnea * Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss. Exclusion Criteria: * Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * Have poorly controlled hypertension. * Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * Have any of the following cardiovascular conditions within 3 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure. * Have a history of symptomatic gallbladder disease within the past 2 years. * Have a lifetime history of suicide attempts.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'The CWMM protocol includes screening assessments plus a framework for the subsequent intervention, which is the primary purpose of the protocol.', 'primaryPurpose': 'SCREENING', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 390, 'type': 'ESTIMATED'}}
Updated at
2024-04-15

1 organization

3 products

1 indication

Product
LY3841136
Indication
Obesity
Product
LY3305677
Product
Placebo